Impact of mepolizumab on symptom severity in patients with hypereosinophilic syndrome - 01/02/21
Doi : 10.1016/j.jaci.2020.12.506
Florence Roufosse 1, Joseph Butterfield, MD FAAAAI 2, Robyn von Maltzahn, MSc 3, Linda Nelsen, MHS 4, Jane Bentley, MSc 5, Namhee Kwon, MD PhD 6, Jonathan Steinfeld, MD 4
1 Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
2 Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
3 GSK, London, UK
4 GSK, Collegeville, PA, USA
5 GSK, Stockley Park, Uxbridge, Middlesex, UK
6 GSK, Brentford, London, UK
446
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB139 - Febbraio 2021 Ritorno al numero
Articolo precedente
- An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes (HES)
- Michael Chen, Praveen Akuthota, Timothy Lax, Sameer Mathur, Princess Ogbogu, Thanai Pongdee, Marc Rothenberg, Florence Roufosse, Dagmar Simon, Miguel Stein, Sa Wang, Michael Wechsler, Amy Klion, Bruce Bochner
- Effect of Dupilumab Treatment on Blood Eosinophil Levels in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis (EoE), or Atopic Dermatitis (AD)
- Michael Wechsler, Amy Klion, Pierluigi Paggiaro, Parameswaran Nair, Delphine Staumont-Salle, Amr Radwan, Robert Johnson, Upender Kapoor, Faisal A. Khokhar, Nadia Daizadeh, Zhen Chen, Elizabeth Laws, Juby Jacob-Nara, Leda Mannent, Marcella Ruddy, Paul Rowe, Yamo Deniz
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?